A notable advancement in glucose care is emerging with the approval of tirzepatide at a dosage of 45mg. This new offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and provides a https://alexiabjqq287342.bleepblogs.com/41167434/revolutionary-development-tirzepatide-dose-for-glucose-control